Medical devices, healthcare technology and the business of care
PMA approval · P030050

SCULPTRA AND SCULPTRA AESTHETIC

Q-Med AB · Decision date Aug 3, 2004

MEDTECHLEDGER EXPLANATIONP030050

What did the FDA approve?

The August 3, 2004 approval for SCULPTRA (P030050) covers the device as intended for restoration and/or correction of the signs of facial fat loss, termed lipoatrophy, in people with human immunodeficiency virus. The applicant is Q-Med AB, and the product code LMH places it in the implant, dermal, for aesthetic use category under the general and plastic surgery specialty.

The decision field records an APPR outcome, but the supplement type and supplement reason fields are absent. This means the record does not state whether the action is an original PMA approval or a supplement, and no manufacturing or labeling change is described. The statement reports an intended use; it does not provide independent evidence of safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR SCULPTRA. THE DEVICE IS INTENDED FOR RESTORATION AND/OR CORRECTION OF THE SIGNS OF FACIAL FAT LOSS (LIPOATROPHY) IN PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Aug 3, 2004

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030050
Regulatory pathway
Premarket approval application
Applicant
Q-Med AB
Product code
LMH
Decision code
APPR
Decision date
Aug 3, 2004
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Q-Med AB
Product code
LMH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P030050 received

    Application receipt date recorded by FDA.

  2. P030050 · FDA decision

    APPR

  3. P030050/S056 · Related supplement

    SCULPTRA (injectable poly-L Lactic acid)

Timeline entries are records held by MedtechLedger for P030050. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030050

Product / regulatory recordCompanyPathwayDecision dateSource
Q-Med ABPMA supplementSep 17, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Q-Med AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seminariegatan 21, Uppsala, SE-752-28

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records